

Performance in Delivering - Q1: 2015/2016 (1st July 2014 - 30th June 2015)

Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time	Comments
13/EE/0276	CCRN 2569 (HCV) A Phase 3B Randomized, Open-Label Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection	10	31/12/2014	Open	N	FP
13/SC/0463	CCRN 2459 (Hep C) A multicenter, open-label, randomized, 3-arm, phase II profiling trial of pharmacokinetics, pharmacodynamics and safety of DEB025/Alisporivir in combination with ribavirin therapy in chronic hepatitis C genotype 2 and 3 treatment naïve patients	8	30/12/2014	Closed	N	FP
13/LO/0520	OCTAVE, Ranibizumab in neovascular age-related macular degeneration(CRFB002A2405)	4	11/04/2016	Closed	Y	FP
12/NE/0342	CCRN 1025 (NASH) A Study to Evaluate the Efficacy and Safety of GFT505 80mg and GFT505 120mg once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH).	4	01/03/2015	Closed	N	FP

12/SC/0024	CRYSTAL CRFB002E2401 A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)	6	27/02/2015	Closed	Y	FP
12/SC/0025	BRIGHTER (CRFB002E2402) A 24-month, phase IIIb, open-label, randomized, activecontrolled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO)	6	29/05/2015	Closed	N	FP
12/LO/0372	ALLERGAN DME 206207-024 A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macula Edema	4	30/09/2014	Closed	Y	FP

12/YH/0246	BPH-6; A Urolift (R) Post Market Multi-Center Randomized Study To compare the UroLift System Treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men over the age of 50.	10	01/12/2014	Closed - In Follow Up	Y	FP
13/EM/0254	PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)	12	01/08/2015	Closed	N	FP
10/NIR02/64	GOLIATH Greenlight A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate with the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia	15	14/12/2015	Closed	Y	FP
14/SC/0262	CCRN 3322 SAFARI (AMD) A Phase IV, prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching From intravitreal Aflibercept to Ranibizumab 0.5mg.	5	30/10/2016	Open	N/A	FP

13/EE/0241	CCRN 2278 - SIGNATURE Secukinumab in patients with moderate to severe active, chronic plaque psoriasis who have failed on TNFa antagonists: A clinical trial evaluating treatment results (SIGNATURE Study CAIN457AGB01)	2	31/03/2016	Closed - Follow Up	N/A	FP
13/LO/0174	CCRN 2073 (Pre-eclampsia SALURATE) A study of Salivary Uric Acid as a predictor of pregnancy-induced hypertension or pre-eclampsia.	100	30/11/2014	Closed - Follow up	Y	FP
14/NW/0130	RESPONSE (NT100) "A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)."	5	30/06/2015	Open	N/A	FP
13/WM/0491	Proteus Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy. (PROTEUS)	6	01/08/2015	Closed - Follow up	N/A	FP

14/EM/0001	TREND (CRFB002A2411) A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration	6	17/12/2015	Closed - In Follow Up	N	FP
14/SC/0100	JETREA FIRSTLINE (ALCON) - Assessment of Patients Treated With JETREA® for Vitreomacular Traction	6	30/09/2015	Closed	Y	FP
13/WM/0234	CCRN 2194 (Breast Reconstruction) A Prospective, Multicenter, Controlled Study of implant-based breast reconstruction, measuring the safety, effectiveness and cost consequences, of Immediate Single Stage Breast Reconstruction with StratticeT Reconstructive Tissue Matrix versus Immediate Two Stage Breast Reconstruction without Strattice	10	31/12/2016	Closed - In Follow Up	N	FP
13/LO/0733	NCRN544 ADAPT AGS-003 + SOC in advanced RCC An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma	4	01/04/2016	Closed	N/A	FP

13/LO/1686	ECLIPSE: Fovista™ and Lucentis® compared to Lucentis® alone in patients with AMD (Ophthotech) A Phase 3 randomised, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration.	5	22/07/2017	Closed - Follow up	N/A	FP
14/NW/1068	LORELEI: GO28888 Neoadjuvant Letrozole and GDC0032 in ER+/HER2Breast Cancer	6	06/03/2017	Open	N/A	FP
14/EE/1001	A 6 month, prospective, randomised, multicenter, placebo-controlled safety study of OTO-104 given at 3-month intervals by intratympanic injection in subjects with unilateral Meniere's disease followed by a 6-month open-label extension	4	25/02/2016	Open	N/A	HWP
13/SC/0054	GLORIA-AF	86	31/12/2020	Open	N/A	HWP
13/NW/0462	ACACIA: NCRN611 - Dose Finding Study of APD403 in CINV	15	30/01/2015	Closed	yes	HWP
14/YH/1090	QUIET-1	4	31/08/2015	Open	N/A	FP